CagriSema achieves >20% weight loss in adults with obesity. Content TribeMD} Eloralintide Lilly's Amylin Agonist Outperforms Novo's Cagrilintide at 48 Weeks Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet